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Tissue macrophages play important roles in maintaining homeostasis in most organs of the body including the
brain where microglia represent the resident phagocytic cells of this compartment. The possibility of one day
harnessing macrophage plasticity to treat or ameliorate disorders including obesity, cancer, organ damage,
intestinal disorders, neurodegeneration, and cardiovascular disease in which these cells play a role, is a very
exciting prospect. Inflammatory signaling is required for regenerative repair, healing, and pathogen clearance
functions. However, when the inflammatory response persists in a chronic fashion over an extended period of time,
damage to neurons is followed by neuronal injury and dysfunction. Macrophages in the brain are heterogeneous
arising from tissues during embryogenesis, and in the adult, from bone marrow derived monocytes that enter
through the blood–brain-barrier. While much of our insight regarding macrophage functional subtypes has
been garnered through elegant studies in mice, which are amenable to genetic manipulation, far less is
known about such cells in human tissues, and particularly in the brain under normal, disease, or injurious
conditions. In this regard, non-human primate models for human immunodeficiency virus have been extremely
useful for understanding the contribution of bone marrow-derived monocytes in neurological disease and their
interaction and impact on the activation state of resident microglia in the brain. This review will focus on
what has been learned from the rhesus macaque models about the types of macrophages present in the
brains of animals with encephalitis. In vitro studies, which have used human blood monocytes differentiated
into macrophages to address the question of macrophage subsets in HIV infection will be highlighted. Recent
insights on macrophage phenotype and persistent inflammation in the brain in HIV-associated neurocognitive
disorder from immunohistochemical studies on human autopsy tissue will be examined.
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The possibility of one day harnessing macrophage plasti-
city to treat or ameliorate disorders including obesity,
cancer, organ damage, intestinal disorders, neurodegen-
eration and cardiovascular disease in which these cells
play a role, is a very exciting prospect. With the elegant
studies done in mice, much has been learned about the
ontogeny of tissue macrophages, their ability for localCorrespondence: abrown76@jhmi.edu
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in any medium, provided the original work is pproliferation and the recruitment of monocytes from the
adult bone marrow under normal homeostatic condi-
tions versus in disease states or in the case of injury
[1-3]. In this review, some of the seminal findings from
mice on monocyte-macrophage development will be
highlighted and then the focus turned on the nervous
system with an emphasis on recent findings on macro-
phage phenotype in non-human primates and humans
as it relates to human immunodeficiency type 1 (HIV)-
mediated neuropathogenesis.en Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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Macrophages were first identified in 1841 as inflammatory
corpuscles in damaged brain, as foam cells by Virchow
in 1846, stained by Weigert and Golgi in 1873, and its key
function as a mediator of phagocytosis was reported by
Metchnikoff in 1882 [4]. The central nervous system, and
particularly the brain, represents the farthest reaches
of the frontier, as any future translational therapeutic
approaches must, based on our current understanding,
surmount the blood–brain-barrier, penetrate into the brain
parenchyma, and localize to the affected site in order to
have a beneficial effect.
It is now well established, based on a series of recent
elegant studies using mouse genetics, lineage fate map-
ping techniques, and transcription profiling, that embryonic
monocytes give rise to the majority of tissue macrophages
in an adult animal except for in the intestine, heart, and
skin [1-3]. Moreover, these tissue macrophages are cap-
able of self-renewal. However, in the context of neuronal
injury and infection, patrolling monocytes/macrophages
from the bone marrow will invade the brain. In this
regard, trafficking of CCR2 expressing monocytes to the
brain in a model of Alzheimer’s disease, plays a key role in
ameliorating the toxic effect of amyloid accumulation [5].
In the adult animal, myeloid cells develop in the bone
marrow from a CD34+ hematopoietic stem cell that gives
rise to a common myeloid progenitor that can migrate
into tissues [6,7]. Turnover studies in mice suggest that
monocytes circulate in the blood for 1–3 days before
entering tissues where, depending on signals received
from local resident macrophages [1], they differentiate
into mature cells with distinct morphology and function.
Whether different subpopulations of monocytes give rise
to specific types of tissue macrophages is not currently
fully understood, but there is agreement that the presence
of the fractalkine receptor CX3CR1 marks inflammatory
monocytes that migrate into tissues in response to its
ligand [8,9].
At least three distinct populations of monocytes have
been identified in human blood based on the expression
of the cell surface receptors: 1) CD14hiCD16− (classical)
which also express CCR2hi, CX3CR1
lo and represent
80-90% of total monocytes, 2) the CD14+CD16hi (non-
classical), and 3) the CD14hiCD16lo (intermediate) proin-
flammatory monocytes that also express CX3CR1, and low
levels of CCR2, and are found in the blood at 5-10% [10].
This latter population is preferentially infected by in HIV
[11] and infiltrates the brain during infection [12,13].
Moreover, transcriptional profiling suggests that distinct
genetic programs distinguish the three subsets [14,15].
What we do not yet know is whether these subpopulations
can be reprogrammed into different subtypes. In vitro,
and likely in microenvironments within tissue compart-
ments, specific cytokines can polarize monocytes todevelop along different effector pathways that have been
called M1 or M2, analogous to the nomenclature used for
T-cell subsets [16-18]. Several excellent reviews discuss
the discovery and spectrum of phenotypes and functional
characteristics of these subtypes of macrophages [18,19].
In addition to inflammatory-directed polarization, the
determinants of macrophage morphology and function
may in part, be governed by the cells in the microenviron-
ment with which macrophages interact. For example, a
subtype of macrophage found in the intestine, the muscu-
laris macrophages, associate very tightly with enteric neu-
rons to help regulate intestinal peristalsis [20]. Analogous
to the microglia-neuron regulatory signaling mechanism
using fractalkine ligand on neurons and fractalkine receptor
on microglia, muscularis macrophages secrete bone mor-
phogenetic protein 2 (BMP2), which activates the BMP re-
ceptor on enteric neurons [20]. Microglia, the resident
macrophages in the brain, assume an ameboid shape when
engaged in phagocytic functions. Microglia display an ex-
tensive ramified morphology under normal homeostatic
conditions during which they continually make contact
through extended finger-like projections to neurons in their
vicinity [21,22]. Microglia also play critical roles in shaping
neuronal networks during development, and in the adult
animal by modulating synaptic transmission [21,23].
Within the brain, macrophage phenotype varies with
their location in this tissue. Perivascular macrophages,
as the name implies, are located intimately with vessels
and enter from the blood circulation into the brain at
a low level during normal conditions, and at higher fre-
quency in the context of damage or invasion of the brain
by a pathogen. Choroid plexus macrophages and menin-
geal macrophages, which are closely associated with the
meninges, the thin blood vessels that line the brain, express
MHC class II and costimulatory molecules. Parenchymal
macrophages include the microglia population and cell
surface markers such as CD68, Iba1, and CD163 stain both
cell types [24]. Moreover, it is possible that infiltrating
macrophages that move deeper into the parenchyma
are able to do so because the appropriate transcriptional
program has been initiated and recognized within the local
microenvironment. Indeed, blood monocytes can home
to the brain when microglia are experimentally depleted in
mice [25]. However, the bone marrow-derived microglia
are not able to penetrate deeply into the brain parenchyma,
which suggests the possibility that they lack the genetic
instructions to do so and/or that they do not receive the
proper secondary signals perhaps because they are not in
the correct location [25].
Traffic across the blood–brain-barrier is strictly regulated,
but many pathogens are able to gain entry through mono-
cytes, which are able to extravasate across. HIV enters the
body through mucosal sites where it infects resident macro-
phages, dendritic cells, and CD4+ T-cells at these sites
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HIV enters the brain rapidly after infection. Entry into the
brain was shown in a case of human iatrogenic transmis-
sion, and to occur within three to fifteen days depending
on the experimental monkey model examined [26-29]. In
the absence of treatment, encephalitis occurs in ~20-30%
of infected individuals, which is characterized pathologic-
ally by the presence of multinucleated giant cells, micro-
glia nodules, microgliosis, astrocytosis, and abundant
CD68+ macrophages staining for HIV antigens [30]. As
not all HIV-infected individuals develop CNS dysfunction,
there is a role for host genetics in conferring susceptibility or
resistance to the development of cognitive impairment [31].
The simian immunodeficiency virus (SIV) non-human
primate models of HIV infection have been invaluable in
adding to our understanding of the central role of mac-
rophages as initiators of an inflammatory cascade, which
ultimately results in neuronal damage and dysfunction
[32,33]. Analyses of blood monocytes from infected indi-
viduals with HIV-associated dementia detected an expan-
sion of the CD14 + CD16+ subset [12], which was later
confirmed in SIV-infected monkeys. Indeed, monocyte
turnover in the bone marrow is a better predictor of pro-
gression to AIDS than CD4+ T-cell count and plasma viral
load [34,35]. A very recent set of studies suggests a mech-
anism for CCR2/CCL2 signaling in the recruitment and
trafficking of CD14 + CD16+ monocytes into the brain in
HIV-associated cognitive impairment [36,37]. The CD14 +
CD16+ monocytes that crossed an artificial blood–brain-
barrier model as well as those found in the CSF of in-
dividuals with HIV-associated cognitive impairment, were
found to preferentially express CCR2 [37]. Moreover, anti-
body against the tight junction protein JAM-A and adhe-
sion molecule ALCAM was able to block the accumulation
of CD14 + CD16+ monocytes [38]. The macrophage
marker CD163 is present on CD14 +CD16+ blood mono-
cytes expanded in SIV encephalitis and these cells are be-
lieved to be the bone marrow derived CD34+ precursors
of the CD163+ perivascular macrophages seen in the brain
[39-41]. Moreover, CD68 + CD163+ macrophages accumu-
late in the CNS in SIV-infected monkeys and in human
brain tissue from HIV-infected individuals [34,39-42]. In
SIV encephalitis, productively infected CD14 + CD16 +
CD163 + CD45hi perivascular macrophages are abundant.
The myeloid marker MAC387 is found on BrdU+ mono-
cytes/macrophages in SIV-infected animals in the early
stages of CNS invasion only when inflammation is abun-
dant [43]. In contrast, in chronic lesions CD68 + CD163+
macs are most highly represented in SIV-infected animals
and in HIV-infected human with encephalitis [34,39].
Moreover, MAC387 + CD163-CD68-CCR2- macrophages
do not appear to be productively infected with HIV. Multi-
nucleated giant cells, which are the hallmark of fulminant
HIV replication in macrophages, expressed CCR2 andCD68 [43]. Collectively, these data suggest the possibility
that HIV-infected and uninfected M1-type macrophages
may be present early, and as the host attempts to downreg-
ulate the immune response, M2-type macrophages become
more abundant [44]. In in vitro monocyte-derived macro-
phages (MDM), HIV replication in M1 and M2 macro-
phages is reduced, however the extent of the inhibition
varies with the stimuli used [45,46]. Microarray analyses
on HIV-infected MDM have shown that the production
of proinflammatory cytokines is increased through a
TLR-independent pathway suggesting that HIV infection
induces an M1-type milieu [47]. A proteomic study sug-
gested that M1-HIV infected macrophages cocultured
with T-regulatory cells can shift to an M2 phenotype,
which was associated with neuroprotection [48]. Further
study of the potential role played by M1 and M2 type
macrophages in HIV CNS infection is required.
There are currently two approaches for investigating
the contribution of human macrophage phenotype as it
relates to HIV infection: 1) with in vitro culture models
based on the isolation and differentiation of monocytes
isolated from the blood (monocyte-derived macrophages
or MDM) and 2) immunophenotyping using brain tissue
obtained at autopsy. Monocyte isolation methods vary
from low purity using adherence to plastic, to density
gradient centrifugation, elutriation, or the use of positive
or negative immunomagnetic bead selection for example
for CD14+ cells. Each of these methods has their advan-
tages and drawbacks, which relate to the level of purity,
yield, and the inadvertent induction of cellular activa-
tion. Culture conditions can also vary widely and may
make comparisons between laboratories difficult. This
topic has been recently addressed and recommendations
made [19].
We have used a standardized culture model for several
years in conjunction with a recombinant HIV that en-
codes the enhanced green fluorescent (GFP) gene in a
portion of the viral genome that is expressed early dur-
ing infection [49-51]. Using flow cytometric analyses, we
identified a consensus surface activation marker signa-
ture (SAMS), CD14+CD69+CD86+CD68lo on a subpopu-
lation of MDM in which HIV replication was active [52].
Interestingly, the presence of CD69, but not CD14 or
CD86 on the cell surface was dependent on the expression
of the viral protein Nef in the infected macrophage. Nef is
essential for disease pathogenesis in vivo, for robust repli-
cation in primary T-cells and macrophages in vitro, and
helps HIV to evade the immune response through mul-
tiple mechanisms [53-57]. Induction of CD69 expression
on murine macrophages treated with LPS, TNF-α or IFN-γ
and LPS has been reported, however relatively little is cur-
rently known regarding the function of CD69 on this cell
type [58]. One study suggests that CD69 may have a role
in downregulating immune responses through TGF-γ
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presence together with CD69 suggests that these cells are
highly activated. We understand what may at first seem
paradoxical, that HIV would prefer to replicate in an acti-
vated cell, is that the virus has evolved to use host proteins
as cofactors in the essential steps of reverse transcription,
and transcription of the integrated proviral DNA. These
cofactors are present at sufficient concentrations only in
stimulated cells. At least in this in vitro model, both HIV-
dependent and –independent mechanisms are involved in
the regulation of expression of these innate inflammatory
surface proteins. It remains to be determined whether the
phenotype identified will be recapitulated in human tis-
sues in vivo, however CD14 + CD16 + CD69+ monocyte/
macrophages were previously reported to be expanded in
the brain during HIV infection [12].
In regions of the world where therapy is widely avail-
able, the incidence of HIV encephalitis and full-blown
dementia has greatly diminished [60,61]. However, the
prevalence of milder forms of HIV-associated cognitive
impairment has increased as people live longer with the
infection. Importantly, comorbidities including aging,
illicit drug use, exposure to antiretrovirals, cardiovascu-
lar disease, and insulin resistance could potentially con-
tribute to cognitive impairment [62,63]. A major goal of
the field is to identify the neuropathogenic mechanisms
leading to the persistence of neuronal injury and dys-
function in HIV infection despite complete suppression ofFigure 1 Abundant Iba1/AIF-1 positive parenchymal and perivascular
(brown color) expression in tissue from the occipital lobe of an HIV-in
(ANI). Paraffinembedded human autopsy tissue from the occipital lobe (Na
in citric acid buffer pH 6.0 and slides were stained sequentially with rabbit
followed by incubation with goat-anti-rabbitalkaline phosphatase (AP) seco
FastRed Quanto (ThermoFisher) (red color). Slides were then incubated wit
at room temperature for 2 hrs followed by goat anti-mouse-horse radish p
color). Images were taken on an Axio Observer A1 inverted microscope (Ze
and sharpness was performed with Adobe Photoshop 5.5 using the sameviral replication in the periphery. Much of the macrophage
phenotype data that currently exists utilized autopsy tissue
that predated the widespread use of antiretroviral inhibi-
tors in the developed world.
Hence, there is a need to identify biological markers
that could help predict risk for the development of cog-
nitive impairment, and would serve a predictive function
in assessing the efficacy of current treatments and for
novel therapeutics in development. In this regard, a re-
cent study suggests that individuals with asymptomatic
neurocognitive impairment (ANI) have a 2-6-fold in-
creased risk of progressing to further cognitive decline
[64]. One recurring and prominent feature is the persist-
ence of immune activation. Proinflammatory markers in-
cluding IL-6, sCD14, sCD163 remain elevated in those
on successful anti-viral therapy [63,65]. In part, the per-
sistence of these factors is due to early HIV-mediated
damage to the gastrointestinal tract in which microbial
cell wall components are released into the circulation
[66]. Moreover, the presence of these latter inflammatory
mediators is associated with cognitive impairment in
HIV [67].
Osteopontin (OPN) is a proinflammatory cytokine first
described as early T-cell activation marker 1 that is
expressed in several cell types including T-cells and tis-
sue macrophages [68]. OPN was detected as a cytokine
that was highly upregulated in the brains of monkeys
with SIV encephalitis and later shown to also be elevatedmacrophage/microglia (red color) costain for osteopontin (OPN)
fected individual with asymptomatic neurocognitive impairment
tional NeuroAIDS Tissue Consortium). Antigen retrieval was performed
polyclonal antisera against Iba1/AIF-1 (SIGMA) overnight at 4°C
ndary for 1 hr at room temperature and developed with permanent
h mouse monoclonal antibody to OPN (MAB194, Maine Biotechnology)
eroxidase for 1 hr and developed with 3,3’-diaminobenzidine (brown
iss) at 20x magnification. Adjustment of the image brightness, contrast
settings for each image.
Figure 2 Iba1/AIF-1 positive parenchymal macrophage/microglia (red color) costain for osteopontin (OPN) (brown color) expression in
tissue from the occipital lobe of an HIV-infected individual with minor neurocognitive disorder (MND). Microglia with ameboid
morphology are more abundant than cells with a ramified phenotype.
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neurocognitive disorder [69,70]. Interestingly, OPN en-
hances HIV replication in macrophages by 50% through
mechanisms that involve activation of the NF-κB re-
sponsive viral promoter, perhaps through integrin recep-
tors and also by promoting cell-to-cell adhesion, which
facilitates viral spread [69,71]. Interestingly, OPN levels
in the plasma remain high despite undetectable HIV
viral load, supporting other observations that inflamma-
tory processes remain active [72]. Both HIV-infected and
uninfected inflammatory monocytes have been shown to
be key contributors to the inflammation seen in theFigure 3 Abundant expression of osteopontin (brown color) in Iba1/AIF
(red color) in tissue from the occipital lobe of an HIV-infected individua
HAD cases were significantly elevated compared to normal controls [74].brain [73]. We hypothesized that these cells were the
major source for OPN in the brain of HIV-infected indi-
viduals. However, a recent immunohistochemical study
on autopsy brain tissue suggests that astrocytes are also a
source of OPN, although no significant differences in
expression were seen between the HIV-infected and HIV-
infected with cognitive impairment groups [74]. Unex-
pectedly, however, significant expression of OPN was
detected in cortical neurons of brain tissue from those
with HIV-associated cognitive impairment [74].
HIV-associated neurocognitive disorders (HAND)
is an umbrella term to describe three levels of-1 positive parenchymal and perivascular macrophage/microglia
l with HIV-associated dementia (HAD). Osteopontin in HIV-infected
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tive impairment (ANI) in which individuals show
deficits (greater than one standard deviation) in two or
more cognitive domains, but no impairment of activities
of daily living (ADL); minor neurocognitive disorder
has the same level of impairment as ANI, but ADLs
are mildly affected and HIV-associated dementia (HAD)
represents the most severe form of impairment in which
deficits in two or more cognitive domains is greater than
two standard deviations and there are a severe impact
on ADLs [75,76]. In tissue from an HIV-infected individ-
ual with ANI, with very low viral load in the CSF (19
RNA copies/ml) or plasma (249 RNA copies/ml) who
had been on antiretrovirals, an abundance of double-
stained Iba-1/OPN perivascular macrophages and micro-
glia and parenchymal microglia were detected (Figure 1).
In a case with MND, the microglia appear to be predom-
inantly of the ameboid type with few ramified processes
(Figure 2). This patient at death despite being on therapy
had a plasma viral load of >48,000 copies/ml, a CSF load
of 148 copies/ml and was severely immunosuppressed
with a CD4 T-cell count of 10. A case with HAD dis-
played microgliosis with abundant ameboid and rami-
fied microglia in the parenchyma, and a high level of
OPN expression (Figure 3). This individual at death
had a high plasma viral load of ~40,000 copies/ml, a
CSF load of 2747 copies/ml but a CD4 T-cell level of
299, not indicative of immunosuppression. Another study
also found, as detected by the markers CD16, CD163,
HLA-DR, and GFAP, that for macrophages/microglia and
astrocytes, elevated levels of inflammation in the brain
remained a common feature in HIV-infected individuals
without evidence of encephalitis or productive viral repli-
cation in the brain [77]. Together these results highlight
the variation in microglia activation that persists in the
brain at the individual level and the need for reliable
plasma and/or CSF markers that would allow clinicians to
track smoldering CNS inflammation.
Conclusion
Much research remains to understand the communica-
tion between macrophages and other cells in the CNS.
We need to identify the key inflammatory signals that
are transmitted from the periphery to the brain and vice
versa, which regulate homeostasis [21,78]. Comorbidities
and host genetics are also important contributors that
must be teased out and animal models will continue to
play an essential role in these investigations. At the same
time, human plasma and CSF have shown promise in
uncovering the identity of potential biomarkers [79-85].
In the future, with regards to modulating macrophage
phenotype in the CNS to counter neurotoxicity and pro-
mote regeneration [86], perhaps targeted delivery to the
nasal compartment may provide an alternative portal tothe brain [87]. We should all get excited about the small,
yet significant steps that advance our understanding of
macrophage phenotype, such that one day, we can make
the giant leap to tackle disease and dysfunction in the
MIND.
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